Laitinen Kirsi, Kalliomäki Marko, Poussa Tuija, Lagström Hanna, Isolauri Erika
Department of Paediatrics, Turku University Central Hospital, Turku, Finland.
Br J Nutr. 2005 Oct;94(4):565-74. doi: 10.1079/bjn20051503.
Current research into dietary factors contributing to the development of allergic diseases is directed towards new active approaches instead of passive elimination diets. The present study aimed to investigate the explanatory role of the diet in a probiotic intervention study on the appearance of atopic eczema (AE) in childhood and the safety of perinatal supplementation with probiotics (Lactobacillus rhamnosus strain GG; ATCC 53 103). A prospective follow-up study from birth to 48 months of children (n 159) with a family history of allergic disease was carried out. Outcome measures included growth, dietary intake assessed with 4 d food diaries and their association with AE by logistic regression models. Increased intakes of retinol, Ca and Zn, with perinatal administration of probiotics, reduced the risk of AE, whilst an increase in intake of ascorbic acid increased the likelihood of AE. Perinatal administration of probiotics was safe, as it did not influence the height (mean difference 0.04 (95 % CI -0.33, 0.40) sd scores, P=0.852) or the weight-for-height (mean difference -3.35 (95 % CI -7.07, 0.37)%, P=0.077) of the children at 48 months with and without perinatal administration of probiotics. Up to 48 months, AE did not affect height (mean difference -0.05 (95 % CI -0.42, 0.33) sd scores, P=0.815), but mean weight-for-height in children with AE was -5.1 % (95 % CI -8.9, -1.2 %) lower compared with children without (P=0.010). The joint effects of nutrients and probiotics need to be considered in active prevention and management schemes for allergic diseases.
目前针对导致过敏性疾病发展的饮食因素的研究正朝着新的积极方法而非被动的排除饮食法展开。本研究旨在探讨饮食在一项益生菌干预研究中对儿童特应性皮炎(AE)出现的解释作用以及围产期补充益生菌(鼠李糖乳杆菌GG菌株;ATCC 53103)的安全性。对159名有过敏性疾病家族史的儿童进行了从出生到48个月的前瞻性随访研究。结果指标包括生长情况、通过4天食物日记评估的饮食摄入量以及通过逻辑回归模型评估其与AE的关联。围产期服用益生菌时,视黄醇、钙和锌摄入量的增加降低了AE的风险,而抗坏血酸摄入量的增加则增加了患AE的可能性。围产期服用益生菌是安全的,因为它不影响48个月时服用和未服用围产期益生菌的儿童的身高(平均差异0.04(95%可信区间-0.33,0.40)标准差分数,P = 0.852)或身高体重比(平均差异-3.35(95%可信区间-7.07,0.37)%,P = 0.077)。在48个月时,AE不影响身高(平均差异-0.05(95%可信区间-0.42,0.33)标准差分数,P = 0.815),但与未患AE的儿童相比,患AE儿童的平均身高体重比低5.1%(95%可信区间-8.9,-1.2%)(P = 0.010)。在过敏性疾病的积极预防和管理方案中需要考虑营养素和益生菌的联合作用。